MariTide (Maridebart Cafraglutide, Investigational)

MariTide (maridebart cafraglutide) by Amgen is a novel investigational antibody-peptide conjugate that uniquely agonizes GLP-1 while antagonizing GIP—the inverse mechanism of tirzepatide, offering a distinct metabolic pathway. Phase 2 data in the New England Journal of Medicine showed approximately 20% weight loss in non-diabetic adults after 52 weeks and about 17% in those with type 2 diabetes, with HbA1c reductions of up to 1.6 percentage points. Crucially, MariTide demonstrated sustained weight loss for up to 52 weeks after treatment stopped, a durability advantage over peptide-based GLP-1s like Ozempic (semaglutide injection), whose effects wane quickly. Its most disruptive feature is once-monthly dosing, potentially once-quarterly, versus weekly injections for all current GLP-1s. However, Phase 2 results fell short of analyst expectations, and Phase 3 trials are ongoing through 2026-2027.